PICARD MEDICAL INC
PMINYSE AMERICANTrading Snapshot
- Day Range
- $4.41 – $4.54
- 52-Week Range
- $2.65 – $684.00
- Volume
- $2.90B
- Avg Volume
- $2.80B
- Shares Outstanding
- 2.1M
- Next Earnings
- Nov 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $5M
- Last Q Revenue
- $3M
- P/E Ratio
- -0.2
- P/S Ratio
- 1.5x
- EPS (TTM)
- $-15.08
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +2.3%
Why Investors Own PMI
- ✓High-growth profile — revenue up +10.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 47% gross margin and 27% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
PICARD MEDICAL INC
PMI
StockOtter · stockotter.spaceAbout PICARD MEDICAL INC
Picard Medical, Inc., through its associated companies, is dedicated to the entire process of medical device commercialization, from initial design and manufacturing to production, distribution, marketing, and sales. A key product in its portfolio is the SynCardia TAH, a sophisticated total artificial heart specifically engineered to supplant a failing human heart in individuals afflicted with advanced cardiac disease. The firm's market presence extends across the United States, Europe, and other international regions. Established in 2021, Picard Medical maintains its primary operations in Tucson, Arizona, functioning as a direct subsidiary of Hunniwell Picard I, Llc.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Kuehn Law Encourages Investors of Picard Medical Inc. to Contact Law Firm
NEW YORK, Sept. 9, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Picard Medical Inc. (NYSE AMERICAN: PMI) breached their fiduciary du
PICARD MEDICAL INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Picard Medical, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Picard (PMI) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in Picard betwee
Picard Medical Reports Second Quarter 2026 Financial Results
- Revenue Increases 39% and Net Loss Decreases 16%- Year-to-Date Revenue Increases 50%, with ~$0.9 Million in Gross Profit TUCSON, Ariz., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Pica
/C O R R E C T I O N -- Fundstrat Capital/
/C O R R E C T I O N -- Fundstrat Capital/ PR Newswire NEW YORK, June 9, 2026 In the
Picard Medical / SynCardia Presents Emperor Total Artificial Heart Architecture for the First Time at IEEE EMBC 2026
–First public scientific presentation provides the biomedical engineering community with its first detailed view of the next-generation total artificial heart platform– –First public scientific presentation provides the
Picard Medical / SynCardia to Present Next-Generation Emperor Total Artificial Heart Technology at IEEE EMBC 2026
-First scientific presentation of the Emperor Drive System architecture to the biomedical engineering community- TUCSON, Ariz., July 27, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) ("Picard" or the